Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation + vancomycin
- Development stage
- Unknown
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Colonoscopy, Rectal, Nasogastric
01
Overview
Fecal microbiota transplantation (FMT) + vancomycin is a combination therapy used primarily for the treatment of Clostridioides difficile infection (CDI). This approach combines oral vancomycin (an antibiotic that targets C. difficile) with the transplantation of fecal matter from a healthy donor into the gastrointestinal tract of a patient to restore healthy gut microbiota. The combination has shown superior efficacy compared to vancomycin alone, particularly for recurrent or severe C. difficile infections. FMT works by replenishing the natural flora of the GI tract that has been harmed due to antibiotic use or overgrowth of harmful bacteria, while vancomycin helps to control the C. difficile infection directly. The FMT component can be administered through various routes including colonoscopy, enema, nasogastric tube, or oral capsules.
- Other names
- FMT + vancomycinstool transplant + vancomycinbacteriotherapy + vancomycin
02
Targets
D-Ala-D-Ala (D-Ala-D-Ala terminus)
Beyond the preview
Go deeper on fecal microbiota transplantation + vancomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation + vancomycin.